| Autor: |
Prandoni P; Arianna Foundation on Anticoagulation, Bologna, Italy. Electronic address: prandonip@gmail.com., Haas S; Formerly Technical University of Munich, Munich, Germany., Fluharty M; Thrombosis Research Institute, London, United Kingdom., Schellong S; Medical Department 2, Municipal Hospital Dresden, Germany., Goto S; Department of Medicine (Cardiology), Tokai University School of Medicine, Japan., MacCallum P; Department of Hematology, Queen Mary University of London, London, United Kingdom., Tse E; Department of Medicine, Queen Mary Hospital, Hong Kong., Pieper K; Thrombosis Research Institute, London, United Kingdom., Kayani G; Thrombosis Research Institute, London, United Kingdom., Kakkar A; Thrombosis Research Institute, London, United Kingdom. |
| Abstrakt: |
Competing Interests: Declaration of competing interest Paolo Prandoni has received personal fees from Bayer Pharma AG, Pfizer, Daiichi-Sankyo, Italfarmaco, Alfasigma and Sanofi. Sylvia Haas has received personal fees from Bayer, BMS, DaiichiSankyo, Pfizer, Sanofi, outside the submitted work. Shinya Goto has received quality fee from the American Heart Association and received Steering Committee fee from Duke University. Karen Pieper has consultancy with Johnson & Johnson, Element Science, Artivion, Novartis. Eric Tse has received consultancy fee from Merck Sharp & Dohme. Ajay K Kakkar has received grants from Bayer, Sanofi and Anthos; personal fees from Sanofi, Bayer and Anthos. The other authors report no conflicts of interest. |
Full Text from ScienceDirect